HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform

Executive Summary

“If I were in your shoes or in Commissioner Gottlieb’s shoes I wouldn’t wait another day to require a warning on all [talc-containing cosmetic] products,” EWG’s Scott Faber told a House Oversight and Reform subcommittee March 12, while maintaining that large-scale regulatory changes are what's truly needed to protect users of talcum powders and other personal-care items.

You may also be interested in...



Tylenol Relieves Pain For J&J Consumer As Baby Care Relaunch Loses Steam

Tylenol brand boosts J&J US OTC sales 8.4% to $477m, helping balance a 24.1% decline in baby care sales due to restocking reformulated Johnson’s Baby line in 2018, mostly in the US. Firm reports consumer health sales in the US were up 1.7% to $1.39bn.

Claire’s Caves, Recalls Makeup Products Following FDA’s Asbestos Finding

The jewelry and cosmetics retailer announced March 11 that it is voluntarily recalling selected lots of three makeup products due to the “possible presence of asbestos fibers.” FDA issued a safety alert the previous week that has made Claire’s the latest poster child for cosmetics regulatory reform.

Rep. Pallone’s Discussion Draft For Cosmetics Reform Closely Mirrors Reintroduced Feinstein/Collins Bill

A bipartisan proposal from new House Energy & Commerce chair Frank Pallone and Rep. John Shimkus, R-Ill., is a near-facsimile of the reintroduced Personal Care Products Safety Act in the Senate. This could set the stage for simultaneous consideration and expeditious movement in both chambers of Congress.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel